• Cancel
    Date：2020-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=525

    Tea brand CHALI (the “Company”) recently announced the closing of a Series B financing round of RMB 100 million. This round of financing was led by Country Garden Venture Capital, with CEC Capital Group’s investment fund and Wens (Guangdong) also participating in this round of investment. The proceeds from the financing will primarily be used for channel expansion and the construction of the Company’s Nansha R&D center. CHALI was established in August 2013. The Company is positioned as a packaged tea products and retail store brand. Its main products include herbal and fruit blended teas with over 600 million tea bags sold. During this year’s Double 11 Festival (November 11) in China, CHALI’s online sales ranked third in T-mall’s tea category and first in the herbal tea category. On JD.com, CHALI’s Peach Oolong Tea pouch sold 140,000 units, ranking No. 1 in single product sales in JD’s tea categories.

  • Cancel
    Date：2020-09
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=510

    CEC Capital Group participates as a lead investor On September 1, 2020, Thery Pharm (the “Company”), a benchmarking company for specialty Active Pharmaceutical Ingredients (APIs), announced the completion of a Series C financing round of nearly RMB 250 million. This financing round was jointly led by SND Ventures Group and CEC Capital Group. New investors include Golden Partners Capital, Suzhou Guofa Venture Capital, and Tahoe Venture. Existing shareholder Legend Capital also increased its holdings in the Company.

  • Cancel
    Date：2020-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=507

    Freenome, a portfolio company in CEC Capital Group’s Healthcare Fund, announced today that it has completed its Series C financing round of USD 270 million. The financing round was led by Bain Capital and Perceptive Advisors. Freenome was founded in 2015 and is headquartered in San Francisco. In 2017 and 2019, Freenome completed USD 65 million and USD 160 million in Series A and B financings, respectively. Freenome aims to develop simple and accurate blood testing methods to detect and screen early-stage cancers.

  • Cancel
    Date：2020-07

    -

  • Cancel
    Date：2020-05

    -

  • Cancel
    Date：2020-02

    -

  • Cancel
    Date：2020-01

    -

  • Cancel
    Date：2019-12

    -

  • Cancel
    Date：2019-07
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=429

    On July 24th, 2019, Freenome, a well-known US company in the field of cancer screening, announced the completion of a USD 160 million Series B round of financing. The round of financing was led by RA Capital Management and Polaris Partners. CEC Capital pa